New oral drug shows promise for kids with rare RET-Driven cancers
NCT ID NCT03899792
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancers have not responded to standard treatments are participating.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selpercatinib (also called LOXO-292), an oral drug that targets RET gene changes
- What this could lead to
- If successful, this could provide a new targeted treatment option for children with certain hard-to-treat cancers that have RET gene alterations.
- What could go wrong
- This is an early-phase trial with only 36 participants, so results may not apply broadly. The drug may cause side effects or not shrink tumors in many children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTILE FIBROSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Childrens Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
Gustave Roussy
Villejuif, 94805, France
-
Hiroshima University Hospital
Hiroshima, 734-8551, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], 8035, Spain
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
Nemours Children's Health
Orlando, Florida, 32827, United States
-
Rigshospitalet
Copenhagen, 2200, Denmark
-
Royal Children's Hospital
Melbourne, Victoria, 3052, Australia
-
Seattle Children's Hospital Research Foundation
Seattle, Washington, 98105, United States
-
Seoul National University Hospital
Seoul, Korea, 03080, South Korea
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
Texas Childrens Hospital
Houston, Texas, 77025, United States
-
The Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
-
The Children's Hospital for Cancer and Blood Disorders
Aurora, Colorado, 80045, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
University College Hospital - London
London, Greater London, NW1 2BU, United Kingdom
-
University of Minnesota Hospital
Minneapolis, Minnesota, 55455, United States
-
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390-9063, United States
-
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69115, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Glowing dye could help surgeons spot hidden brain tumor cells